Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma

Human Gene Therapy

Volumn 9, Issue 1, 1998, Pages 13-19

  Kopantzev, Eugene ^a   Roschke, Viktor ^a   Rudikoff, Stuart ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CARCINOGENICITY; FEMALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; TUMOR CELL LINE; TUMOR GROWTH;

EID: 0031975423     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1998.9.1-13     Document Type: Article

References (11)

1. ARIENTI, F., SULE-SUSO, J., MELANI, C., MACCALLI, C., BELLI, F., ILLENI, M.T., ANICHINI, A., CASCINELLI, N., COLOMBO, M.P., and PARMIANI, G. (1994). Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. Hum. Gene Ther. 5, 1139-1150.
2. BUBENIK, J., SIMOVA, J., and JANDLOVA, T. (1990). Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol. Lett. 23, 287-292.
3. CAVALLO, F., DI PIERRO, F., GIOVARELLI, M., GULINO, A., VACCA, A., STOPPACCIARO, A., FORNI, M., MODESTI, A., and FORNI, G. (1993). Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 53, 5057-5070.
4. GANSBACHER, B., ZIER, K., DANIELS, B., CRONIN, K., BANNERJI, R., and GILBOA, E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
5. GOODWIN, C.J., HOLT, S.J., DOWNES, S., and MARSHALL, N.J. (1995). Microculture tetrazolium assays: A comparison between two new tetrazolium salts, XTT and MTS. J. Immunol. Methods 179, 95-103.
6. HILBERT, D.M., SHEN, M.Y., RAPP, U.R., and RUDIKOFF, S. (1995a). T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors. Proc. Natl. Acad. Sci. USA 92, 649-655.
7. HILBERT, D.M., KOPF, M., MOCK, B.A., KOHLER, G., and RUDIKOFF, S. (1995b). Interleukin 6 is essential for in vivo development of B lineage neoplasms. J. Exp. Med. 182, 243-248.
8. HOCK, H., DORSCH, M., KUNZENDORF, U., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993a). Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or Interferon gamma. Proc. Natl. Acad. Sci. USA 90, 2774-2778.
9. HOCK, H., DORSCH, M., KUNZENDORF, U., UBERLA, K., QIN, Z., DIAMANTSTEIN, T., and BLANKENSTEIN, T. (1993b). Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res. 53, 714-716.
10. KAWANO, M., HIRANO, T., MATSUDA, T., TAGA, T., HORII, Y., IWATO, K., ASAOKU, H., TANG, B., TANABE, O., and TANAKA, H. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332, 83-85.
11. ZHANG, X.G., GAILLARD, J.P., ROBILLARD, N., LU, Z.Y., GU, Z.J., JOURDAN, M., BOIRON, J.M., BATAILLE, R., and KLEIN, B. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83, 3654-3663.